Shopping Cart 0
Cart Subtotal
USD 0

University of California Los Angeles - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

University of California Los Angeles (UCLA) a subsidiary of University of California, is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The university's services include support services, campus services, graduate degree and undergraduate degree program and also provides research services in libraries, museums, film, music archives, art galleries, horizon-broadening, humanity-serving of California. UCLA operates through its departments including anthropology, archaeology, applied linguistics, architecture and urban design, bio-engineering, bio-medical research, dentistry and digital humanities. The university also conducts variety of programs for students in community operations. UCLA is headquartered in Los Angeles, California, the US.

University of California Los Angeles-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of California Los Angeles, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

University of California Los Angeles, Medical Devices Deals, 2012 to YTD 2018 11

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

University of California Los Angeles, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles 14

Vaccinex Enters into Agreement with UCLAs Jonsson Comprehensive Cancer Center 15

Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 16

Trethera Enters into Research Agreement with University of California, Los Angeles 18

NewBio Therapeutics and University of California Los Angeles Enter into Agreement 19

Bristol-Myers Squibb Enters into Research Agreement with UCLA 20

Zymeworks Enters into Research Agreement with University of California, Los Angeles 21

NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development 22

Licensing Agreements 23

Bloom Science Enters into Licensing Agreement with UCLA 23

Diamyd Medical Enters into Licensing Agreement with University of California 24

Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 25

Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 26

Fibrocell Science Enters Into Licensing Agreement With University of California 27

Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles 28

Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 29

Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles 30

BioTime Enters Into Licensing Agreement With University of California, Los Angeles 31

Asset Transactions 32

Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 32

University of California Los Angeles-Key Competitors 34

University of California Los Angeles-Key Employees 35

University of California Los Angeles-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Joint Venture 38

Recent Developments 39

Government and Public Interest 39

Sep 18, 2018: Researchers find adult stem cell characteristics in aggressive cancers from different tissues 39

Sep 17, 2018: UCLA researchers develop mechanism for characterizing function of rare tumor cells 41

Sep 05, 2018: Metabolism-focused startup aims to shorten time between scientific insight and therapies 43

Aug 29, 2018: New therapy spurs nerve fibers to regrow through scar tissue, transmit signals after spinal cord injury in rodents 44

Aug 17, 2018: Cancer researcher receives USD 100,000 award to study gene therapies 46

Aug 08, 2018: UCLA awarded USD 9.3 million to help provide prostate cancer treatment in the community 47

Aug 07, 2018: UCLA Health joins nationwide clinical trial for acute myeloid leukemia 48

Aug 03, 2018: UCLA awarded USD 1.3 million to help create support system for mental illness 49

Jul 30, 2018: Drugs for heart failure are still under-prescribed, years after initial study 50

Jul 23, 2018: Researchers receive grant to help HIV-positive adults at risk for heart disease 51

Jul 09, 2018: Antibody identifier could speed development of therapies for cancer, other diseases 52

Jun 26, 2018: UCLA researchers develop synthetic T cells that mimic form, function of human version 53

Jun 11, 2018: OneLegacy Foundation Awards USD 100,000 in Grants to Local Medical Centers 54

Jun 06, 2018: Latest Gates Foundation grants will advance research on educational inclusion and global immunization 55

Jun 04, 2018: Researchers discover how colon cancer mutates to escape the immune system 56

May 17, 2018: New algorithm more accurately predicts life expectancy after heart failure 57

May 16, 2018: Lab-confirmed prenatal exposure to Zika is linked to cardiac defects in infants 58

May 14, 2018: UCLA Geriatrics receives USD 13.6 million to evaluate approaches to dementia care 59

May 11, 2018: Study identifies receptor that may be targeted to repair the heart after heart attack, cardiac arrest 60

May 02, 2018: Cancer researcher awarded USD 750,000 to help develop new melanoma treatments 61

May 02, 2018: UCLA: How a small molecule halts the spread of a toxic protein associated with Alzheimer's progression 62

Apr 27, 2018: Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost USD 32 Million Boost from Stem Cell Agency 64

Apr 13, 2018: UCLA study produces clearest images to date of HSV-1, the virus that causes cold sores 66

Apr 12, 2018: Discovery of 4 subtypes of melanoma points to new treatment approaches 67

Apr 12, 2018: Inhibiting metabolism found to be effective in treating aggressive form of lung cancer 68

Mar 14, 2018: Nanostructures created by UCLA scientists could make gene therapies safer, faster and more affordable 69

Mar 07, 2018: Boosting brain's immune cell function improves Alzheimer's symptoms in mice, study finds 71

Mar 06, 2018: Multiple-treatment approach improves survival rates in aggressive prostate cancer, study finds 73

Mar 05, 2018: UCLA receives gift from Broad Foundation for digestive disease research 74

Feb 15, 2018: UCLA scientists receive USD 7.7 million grant to study HIV recurrence 75

Feb 14, 2018: Additional Funding for SMA Care Centers Announced 76

Feb 13, 2018: Newly discovered gene may protect against heart disease 77

Feb 08, 2018: Device that measures cell strength could help identify drugs for asthma, hypertension and muscular dystrophy 78

Feb 08, 2018: Autism, schizophrenia, bipolar disorder share molecular traits, study finds 80

Jan 29, 2018: UCLA scientists use stem cells to study genetics of germ cell tumors 81

Jan 18, 2018: The flu vaccine could get a much-needed boost 83

Jan 12, 2018: Immunotherapy highly effective in treatment of rare skin cancer, study finds 84

Jan 11, 2018: UCLA scientists make cells that enable the sense of touch 85

Jan 09, 2018: Effects of estrogen treatment combat multiple sclerosis in mice 86

Jan 08, 2018: Researchers find potential path to repair nerves damaged by multiple sclerosis 87

Jan 02, 2018: Imaging technique could be 'new ballgame' in drug development 88

Dec 18, 2017: UCLA researchers create skeletal muscle from stem cells 90

Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 91

Dec 11, 2017: Blood flow-sensing protein protects against atherosclerosis in mice 92

Dec 05, 2017: Doctors develop new way to use MRI to predict pregnancy complications 93

Oct 13, 2017: With USD 3M grant from Stand Up to Cancer, UCLA researcher to advance understanding of how a promising new combination therapy could overcome melanoma resistance to immunotherapy 94

Oct 12, 2017: NIH awards almost USD 10 million to UCLA Center for Autism Research and Treatment 95

Oct 09, 2017: Combination treatment targeting glucose in advanced brain cancer shows promising results in preclinical study 96

Sep 19, 2017: National Science Foundation awards USD 800K to researchers using MyLymeData 97

Sep 18, 2017: Behavioral therapy increases connectivity in brains of people with OCD 98

Sep 11, 2017: UCLA Launches CIRM-Funded Cancer Clinical Trial 99

Sep 07, 2017: NIH awards nearly USD 100 million for Autism Centers of Excellence program 100

Sep 06, 2017: UCLA receives USD 8.4 million NIH grant to help liver transplant recipients stay healthier longer 102

Aug 14, 2017: UCLA scientists identify a new way to activate stem cells to make hair grow 103

Aug 09, 2017: Stem cell center trainee receives grant to develop nanotechnologies to treat pediatric cancer 105

Aug 02, 2017: SAMHSA announces USD 6 million in grants to support the International President's Emergency Plan for AIDS Relief Addiction Technology Transfer Centers 106

Jul 26, 2017: UCLA researchers reveal unusual chemistry of protein with role in neurodegenerative disorders 107

Jul 19, 2017: Less Invasive Treatment for Blocked Artery in the Leg is Safe, Review Finds 108

Jul 12, 2017: Electrical stimulation of brain may help people with schizophrenia learn to communicate better 109

Apr 05, 2017: UCLA researchers discover a new cause of high plasma triglycerides 110

Apr 03, 2017: Artificial thymus developed at UCLA can produce cancer-fighting T cells from blood stem cells 111

Mar 09, 2017: Targeting cancer stem cells improves treatment effectiveness and prevents metastasis 112

Feb 27, 2017: Guidelines for treating brain metastases should be overhauled, UCLA study finds 113

Feb 07, 2017: UCLA researchers turn stem cells into somites, precursors to skeletal muscle, cartilage and bone 114

Jan 30, 2017: UCLA will lead USD 21 million, grant-funded study of epilepsy after traumatic brain injuries 115

Jan 24, 2017: Combination therapy for glioblastoma shows promising results in early-stage research 116

Jan 12, 2017: With USD 3.2M grant, UCLA researcher to study cancer patients' response to immunotherapy 117

Jan 10, 2017: Autism biomarker seen as boon for new treatments 118

Product News 119

Nov 27, 2017: UCLA scientists design nanotechnology platform for cancer immunotherapy, inducing immunogenic cell death in pancreatic cancer 119

Oct 03, 2017: New method to measure cell stiffness could lead to improved cancer treatments 120

May 21, 2018: Biomaterial developed at UCLA helps regrow brain tissue after stroke in mice 121

May 01, 2017: Combination therapy could provide new treatment option for ovarian cancer 122

Apr 11, 2018: Scientists tweak CRISPR tool to accelerate genomic editing 124

Apr 04, 2017: Kite Highlights Publication on Breakthrough in Generating Fully Functioning T Cells from Hematopoietic Precursor Cells by Leading Researchers at the University of California, Los Angeles 126

Jan 24, 2017: New tuberculosis therapy could be more potent than current treatments 127

Other Significant Developments 129

Jan 23, 2018: MRIGlobal Immunologist Collaborates with UCLA in Published Study Showing Ebola Survivors May Have Lifetime Immunity 129

Dec 14, 2017: UCLA and Caltech Study Uses Technology Being Commercialized by IsoPlexis To Characterize Cancer Cells Resistant to Targeted Treatments 130

Appendix 131

Methodology 131

About GlobalData 131

Contact Us 131

Disclaimer 131


List Of Figure

List of Figures

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

University of California Los Angeles, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

University of California Los Angeles, Pharmaceuticals & Healthcare, Key Facts 2

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of California Los Angeles, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of California Los Angeles, Deals By Therapy Area, 2012 to YTD 2018 10

University of California Los Angeles, Medical Devices Deals, 2012 to YTD 2018 11

University of California Los Angeles, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles 14

Vaccinex Enters into Agreement with UCLAs Jonsson Comprehensive Cancer Center 15

Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 16

Trethera Enters into Research Agreement with University of California, Los Angeles 18

NewBio Therapeutics and University of California Los Angeles Enter into Agreement 19

Bristol-Myers Squibb Enters into Research Agreement with UCLA 20

Zymeworks Enters into Research Agreement with University of California, Los Angeles 21

NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development 22

Bloom Science Enters into Licensing Agreement with UCLA 23

Diamyd Medical Enters into Licensing Agreement with University of California 24

Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 25

Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 26

Fibrocell Science Enters Into Licensing Agreement With University of California 27

Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles 28

Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 29

Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles 30

BioTime Enters Into Licensing Agreement With University of California, Los Angeles 31

Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 32

University of California Los Angeles, Key Competitors 34

University of California Los Angeles, Key Employees 35

University of California Los Angeles, Subsidiaries 36

University of California Los Angeles, Joint Venture 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

University of California Los Angeles, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.